Breaking News

Dermira's Qbrexza for treatment of excessive underarm sweating gets FDA approval

Dermira Inc. DERM, +four.78% said Friday its Qbrexza material for topical treatment of primary axillary hyperhidrosis, or over the top underarm sweating, was authorized by way of the Food and Drug Administration. Qbrexza is indicated for grownup and pediatric sufferers 9 years of age and older. The biopharmaceutical corporate said the cause of primary axillary hyperhidrosis is unknown, but impacts nearly 10 million people within the U.S. The corporate expects Qbrexza to be available national in pharmacies beginning in October 2018. The stock is lately halted for information till 7:30 a.m. ET. It has tumbled 68% yr so far through Thursday, whilst the iShares Nasdaq Biotechnology ETF IBB, +1.73% has gained 1.1% and the S&P 500 SPX, +0.08% has edged up 1.6%.